Change in Body Weight During Treatment of Advanced Colorectal Cancer

Tuen Mun Hospital

Status: Unknown

Conditions: Weight Loss; Chemotherapy Effect; Cancer, Colorectal; Prognosis

Treatments: Drug: first line systemic treatment for colorectal cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04232748

NTWC/CREC/18027

Details and patient eligibility

About

Colorectal cancer (CRC) is a significant and growing health burden in Hong Kong. According to data from Hong Kong Cancer Registry, CRC ranked the first in incidence and the second in mortality, with around 5,000 new cases diagnosed and more than 2,000 cancer-related mortality in 2014. The investigators aim to evaluate the association between serial weight change during first line treatment and outcomes in patients with metastatic CRC.

Full description

Studies have suggested that exposure to a greater number of chemotherapeutic agents is associated with better survival in metastatic colorectal cancer.

Multiple factors might affect body weight during treatment. Cancer-related symptoms can impair quality of life and appetite. Cachexia syndrome affects around 50% of colon cancer patients and is characterized by cancer-induced catabolism with involuntary weight loss (fat and muscle), patients have increased lipolysis and change in skeletal muscle metabolism, including increased energy expenditure at rest and protein degradation, and decreased protein synthesis. Besides these disease factors, treatment related side effects are common causes of weight loss, such as inability to ingest or digest food effectively due to nausea, vomiting, and malaise. Based on these factors and the hypotheses between tumour control and weight gain, monitoring the serial weight change can have practical value.

Enrollment: 264 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically proven adenocarcinoma of colorectal origin
• Stage IV disease with systemic treatment
• Estimated life expectancy >3 months
• Adequate organ functions

Exclusion criteria

• Eastern Cooperative Oncology Group performance status 3 or above
• Pregnancy
• Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS)
• Past medical history of another cancer

Trial design

264 participants in 1 patient group

stage IV colorectal cancer

Description:

stage IV colorectal cancer on first line systemic treatment are observed for the trend of weight change and treatment outcomes

Treatment:

Drug: first line systemic treatment for colorectal cancer